ARTICLE | Company News

Abbott, AZN to combine cholesterol drugs

July 6, 2006 1:24 AM UTC

ABT and AstraZeneca (LSE:AZN; AZN) partnered to develop and market a single-pill combination of AZN's Crestor rosuvastatin and one of ABT's fenofibrates. The partners will share development costs and profits. Following initial testing, AZN and ABT will select either a Crestor/ TriCor combination or a Crestor/ABT-335 combination for final development and commercialization in the U.S. A regulatory submission is expected in 2009. ...